knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 12:36:01 - browse：9782

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Humana cuts profit projections as Medicare Advantage costs soar

explore

WSS

Prior authorization will have to move faster under new Biden rule

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

World's first CRISPR

Does good food count as health care? Study aims to find out

eGenesis tests gene

focus

knowledge

focus

Cancer drug shortages should be causing more outrage

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

The high cost of giving birth even with insurance

Humana cuts profit projections as Medicare Advantage costs soar

After affirmative action ruling, medical educators look to 'holistic review'

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Supreme Court strikes down use of affirmative action

New brain studies show LSD's effects on the brain in full color

Drug repurposing or repositioning? The language matters

Francis Collins on trust in science and how Covid communications failed

leisure time

Humana cuts profit projections as Medicare Advantage costs soar

Test for long Covid? Researchers find new clue in blood samples

A daunting task: navigating dual Medicare, Medicaid eligibility

Parkinson’s finding may lead to tests and, someday, treatments

Gain of function research would be limited under House proposal

New brain studies show LSD's effects on the brain in full color

focus

leisure time

explore

explore